Advances in kidney cancer drug treatments shake up drug choices

The following article provides a comprehensive summary of the changing landscape in the choice of first and second-line drug treatments for advanced kidney cancer, with input from Dr Eric Jonasch, a professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center and vice chair of the Kidney Cancer Guidelines Committee for the National Comprehensive Cancer Network (NCCN):

Read more here

Share this Post!


Related post

  TOP